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Abstract
Background: Diabetes complicates tuberculosis (TB) treatment including a prolonged time of sputum culture
conversion to negative growth. Since 2013 in Virginia, interventions early in the treatment course have used
therapeutic drug monitoring and dose correction for isoniazid and rifampin after 2 weeks of TB treatment in
patients with diabetes along with nurse manager initiated diabetes education and linkage to care.
Methods: A retrospective cohort study of the state TB registry was performed for patients initiating drug-susceptible
pulmonary TB treatment that were matched for age, gender, chest imaging and sputum smear status to compare time
to sputum culture conversion and other clinical outcomes in the pre-and post-intervention groups.
Results: Three hundred sixty-three patients had documented time to sputum culture conversion in the pre-and
post-intervention periods, including 56 (15%) with diabetes. Seventy-four (57%) of all patients with diabetes
were ≥60 years of age at treatment initiation. Twenty-six patients with diabetes were matched in each group.
Mean time to sputum culture conversion in the post-intervention group was 42 ± 22 days compared to the
pre-intervention group of 62 ± 31 days (p = 0.01). In the post-intervention group 21 (80%) of patients with
diabetes had culture conversion by 2 months compared to 13 (50%) in the pre-intervention group (p = 0.04).
Conclusions: Early interventions for diabetes related TB in the programmatic setting may hasten sputum culture
conversion.
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Background
Tuberculosis (TB) was responsible for 1.5 million deaths
worldwide in 2014 [1]. Global estimates suggest 15% of
all patients with TB also have diabetes mellitus and the
overall prevalence of diabetes is increasing in TB-
endemic regions [2]. Diabetes not only increases the risk
of developing active TB by 3-fold [3–6], but also patients
with diabetes are more likely to have poor microbio-
logical and clinical outcomes when developing active TB
disease compared to those without diabetes, such as a
delayed time to sputum culture conversion to negative
and an increased risk of death [7, 8]. Despite these
associations most initiatives have focused on screening
strategies for diabetes among TB patients, but few have
targeted improving treatment outcomes once diabetes
related TB has been diagnosed.
In 2014, in the state of Virginia, USA, one out of 11
people was diagnosed with diabetes at a mean age of
47.6 ± 1.0 years [9]. Additionally, in 2014 the state had a
TB case rate of 2.4 per 100,000 persons, which was a
10% increase from the prior year. Of those TB cases,
16.7% were reported to have diabetes, a proportion
which had steadily increased over the last decade [10].
In an earlier study from Virginia, TB patients with
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diabetes were 7 times more likely to have slow response
to therapy compared to those without diabetes. Slow
response was defined as persistence of TB-specific symp-
toms, no decrement in acid-fast quantification by smear
microscopy or radiographic changes that were worsening
after 1 month or more of treatment [11]. That study also
noted among slow responders that those with diabetes
had lower concentrations of rifampin compared to those
without diabetes. Lower drug concentration in diabetes
patients may be related to impaired drug absorption
secondary to either delayed gastric emptying or hyper-
glycemia which may influence gastric hydrochloric acid
secretion [12, 13]. While therapeutic drug monitoring
(TDM) had been more routinely used in patients after
the development of slow response, these findings led to
increasing use of TDM earlier in the course of therapy
in an effort to prevent slow response in diabetes related
TB. Hence, in 2013 statewide recommendations were
updated to perform TDM at 2 weeks after treatment ini-
tiation for all patients with diabetes, so-called early
TDM, a process found to be feasible for the majority of
all cases in the state, and during which 21 (76%) of all
diabetes patients tested had peak serum concentrations
of isoniazid, rifampin or both that were below the ex-
pected range [14, 15]. At the same time, other interven-
tions aimed at this subpopulation included more active
laboratory screening for diabetes among TB patients
initiating therapy, and development of an educational
flipchart adapted for nurse to patient counseling
during directly observed therapy to reinforce healthy
living strategies for diabetes and assure linkage to dia-
betes care [16, 17].
Therefore, we sought to compare clinically relevant
outcomes among patients with diabetes initiating TB
treatment in the state before and after the implementa-
tion of these early interventions. The pre-and post-
intervention change in outcomes were also compared
between patients with and without diabetes. Given that
mortality rates from TB are low in the state, the primary
outcome of interest was sputum culture conversion to
negative. Lack of conversion by 2 months has been used
as a predictor of relapse, for example in one study
correlating with a relapse rate of 10% within 1 year [18],
and the time to culture conversion may influence a clini-
cian’s determination of total treatment duration [19–21].
Methods
Subjects
A retrospective cohort analysis was performed among
patients that were newly diagnosed with active TB and
started on anti-TB therapy during the period of January
2009- December 2010 (pre-intervention) and January
2013–December 2014 (post-intervention) in the state.
These dates were used as early TDM for patients with
diabetes was occasionally employed during the years of
2011–2012 prior to formal recommendations. Data
were collected for all patients ≥18 years old from the
state TB registry which captures all treatment initiation.
The study was approved by the institutional review
board at the University of Virginia and the Virginia
Department of Health.
Surveillance data for the pre-intervention group
(2009–2010) and post-intervention group (2013–2014)
included demographics, co-morbidities including human
immunodeficiency virus (HIV) infection and diabetes,
prior TB history and anatomic focus of the current TB
episode categorized as pulmonary, extra-pulmonary or
both. Laboratory report forms for patients with TDM
were reviewed when available. Diabetes diagnosis was
determined by self-report for patients already on anti-
diabetes treatment, or by report of caregivers to nurse
managers or review of medical charts. Laboratory results
for diabetes diagnosis or disease severity, such as glyco-
sylated hemoglobin (HbAlc) or fasting blood glucose,
were not required for reporting in the registry.
Procedures
In Virginia, all cases of active TB are reported to the
Virginia Department of Health and assigned to a nurse
manager. Directly observed therapy is administered by
the nurse manager or a trained outreach worker. In the
pre-intervention time period, TDM was recommended
to be performed only among those patients that demon-
strated slow response usually 8 weeks or more after
treatment initiation. The standard procedure for TDM
was to directly administer medication and then collect
venous blood 2 h later at the time of estimated Cmax.
After collection, serum was separated by centrifugation
at the local health department and transported on dry
ice to the referral laboratory at the University of Florida
where validated high performance liquid chromatog-
raphy or gas chromatography results were available
within 48 h and reported in reference to the expected
μg/mL range [22]. The interpretation of TDM and the
management of slow-responders were referred to state
TB consultants.
In the post-intervention time period, slow-responders
were managed similarly, but additionally all patients
identified as having diabetes were recommended for
TDM. TDM was performed at approximately 2 weeks
after treatment initiation to allow steady state metabol-
ism of anti-TB drugs. In contrast to those with slow
response where dose adjustment after TDM was often
individualized and directed by the state TB consultants,
for those patients with diabetes and early TDM in whom
concentrations were below the expected Cmax range (for
isoniazid 3–5 μg/ml or rifampin 8–24 μg/ml), doses
were adjusted by a single dose increase. For example,
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recommendations stated if the patient was prescribed a
daily dosed rifampin of 600 mg and the drug concentra-
tion was below the expected range, the dose was in-
creased to 900 mg; and for daily dosed isoniazid of
300 mg, the dose was increased to 450 mg [11, 15].
Complications with dose adjustment or major toxicity
were reported to the state TB control program. Follow-
ing early TDM, patients were further monitored for slow
response, and if later identified as slow responders then
referral made to a state TB consultant. In the post-
intervention period recommendations were made to
nurse managers to interview all patients with diabetes
utilizing the educational flipchart and assess the patient’s
understanding of diabetes related TB and linkage to dia-
betes care. Documentation of the use of the flipchart or
linkage to care was not available in the state TB registry.
Per routine in both pre and post-intervention periods,
patients with pulmonary TB had sputum collected
weekly until smear microscopy conversion to negative
and then at least monthly thereafter until culture con-
version. Time to culture conversion was recorded as the
date of collection of the first of two consecutive sputum
samples without mycobacterial growth and calculated in
days from the start of TB treatment initiation.
Statistical analysis
Demographic and clinical characteristics were compared
between all patients in pre-and post-intervention groups
by the χ2 statistic or for continuous variables, the
Student t-test or the Mann–Whitney U test when appro-
priate. The time to sputum culture conversion and the
proportion with culture conversion before 8 weeks were
analyzed among the subgroups of patients with pulmon-
ary TB for whom a time to culture conversion was docu-
mented. Patients were excluded from these analyses if
their M. tuberculosis isolate was resistant to isoniazid,
rifampin, pyrazinamide or ethambutol or if they were
treated with any other second-line drugs. The mean time
to sputum culture conversion and the proportion with
culture conversion before 8 weeks were compared by
the student t-test and χ2 statistic respectively.
To account for the non-randomization of the retro-
spective cohort and to minimize potential selection bias,
non-diabetes and diabetes patients were matched 2:1 on
basic demographics or clinical characteristics previously
reported to influence culture conversion including age
(±15 years), gender, chest imaging with or without cavi-
tary lesions and sputum smear status (positive or nega-
tive at treatment initiation). Non-diabetes and diabetes
patients had time to culture conversion and 8-week cul-
ture conversion compared separately in both the pre and
post-intervention groups. Lastly, to restrict analysis to
known diabetes patients alone, these outcomes were
compared between the pre and post-intervention groups
but due to the smaller numbers of diabetes patients,
matching could only be performed in a 1:1 allocation
(Fig. 1). The matching process and all other statistical
analyses were completed using IBM SPSS statistics for
Windows, version 23.0 (IBM Corp, Armonk, NY).
Results
In total, 539 patients in the pre-intervention period and
391 patients in the post-intervention period were initiated
on TB treatment, including 64 (12%) with diabetes in the
pre-intervention period and 66 (17%) in the post-
intervention period. Including patients from both groups,
those with diabetes had a mean age of 61 ± 15 years
and were older than those without diabetes 41 ±
20 years (p < 0.001). Indeed, 74 (57%) of all patients
with diabetes were ≥60 years of age at treatment initiation.
There were no other differences in baseline patient demo-
graphics between the pre and post-intervention periods
(Table 1).
Fig. 1 Flowchart of patients included for analysis; DM = Diabetes mellitus
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Outcomes among patients with sputum culture
conversion
Including patients from the pre and post-intervention
periods, 363 met criteria (confirmed drug-susceptible pul-
monary TB with documented sputum culture conversion)
for outcomes analyses including 56 (15%) with diabetes
(Fig. 1). Among all patients, the time to culture conversion
was significantly improved from the pre-intervention
group, 56 ± 35 days, to the post-intervention group, 43 ±
28 days (p < 0.001) (Table 2). While this change remained
significant when restricted to non-diabetes patients
that converted 8 days earlier in the post compared to
the pre-intervention period, the improvement in time
to culture conversion was greater for the diabetes pa-
tients with the post-intervention group that converted
on average 19 days earlier (p = 0.02). The same trends
were found for culture conversion before 8 weeks
where for example the proportion among those with
diabetes increased from only 15 (50%) in the pre-
intervention group to 21 (80%) in the post-intervention
group (p = 0.03). The death rate was not significantly
different between the groups (Table 2).
Outcomes among matched cases
When matching non-diabetes and diabetes cases (2:1) and
comparing separately these subgroups within the pre-
intervention and post-intervention periods, patients with
diabetes in the post-intervention group converted earlier
than the non-diabetic patients in the same group (p = 0.08)
and even earlier than both diabetes and non-diabetes pa-
tients in the pre-intervention group (Table 3). Matched
comparison of patients with diabetes only in the pre
and post-intervention groups (1:1) found on average a
20 days’ earlier time to sputum culture conversion (62
± 31 vs 42 ± 22 days; p = 0.01) (Table 4). Only 17 of the
26-matched diabetes had TDM results available for
review, but of those 12 (71%) had a concentration of
rifampin or isoniazid in the range of dose adjustment
(Fig. 2). Those 17 subjects had time to culture conver-
sion 20 days earlier when compared to matched dia-
betes patients in the pre-intervention without TDM
(40 ± 17 vs 63 ± 33; p = 0.02). Of note, no major adverse
effects from dose adjustment were reported to the state
TB control program, but final regimens and doses were
not available for review.
















Age (years, mean ± SD) 43 ± 21 45 ± 21 0.11 60 ± 18 63 ± 13 0.32
Male 309 (57) 216 (55) 0.55 35 (55) 43 (65) 0.28
HIV positive 19 (4) 20 (5) 0.32 0 1 (2) 1.00
Diseases site
Pulmonary only 359 (67) 269 (69) 0.19 53 (83) 54 (82) 0.99
Extra-Pulmonary only 100 (19) 87 (22) 0.67 11 (17) 12 (18) 0.87
Both 80 (15) 35 (9) 0.03 5 (17) 7 (11) 0.55
Sputum culture positive 287 (53) 214 (55) 0.43 36 (56) 40 (61) 0.44
Sputum smear positive 215 (40) 161 (41) 0.15 33 (52) 32 (49) 0.68
Cavitary lesion 181 (34) 131 (34) 0.89 27 (42) 29 (44) 0.86
INH Resistant 43 (10) 26 (9) 0.99 2 (4) 4 (8) 0.42
RIF Resistant 3 (1) 6 (2) 0.70 0 1 (2) 0.47




















Time to culture conversion (days, mean ± SD) 56 ± 35 43 ± 28 <0.001 51 ± 36 43 ± 30 0.003 61 ± 32 42 ± 22 0.02
2 months culture conversion No. (%) 126 (59) 110 (74) 0.002 111 (60) 89 (73) 0.02 15 (50) 21 (80) 0.03
Death No. (%) 5 (2) 2 (1) 0.71 4 (2) 1 (1) 0.65 1 (3) 1 (4) 1.00
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Discussion
This retrospective cohort study assessed the impact of
early interventions among patients with diabetes related
TB and found improvement in microbiological clearance
from the sputum in all patients between the pre and post-
intervention periods but the improvement was more pro-
nounced in those with diabetes. These findings contrast to
most non-interventional studies that note a delay in time
to sputum culture conversion to negative or other worse
outcomes in patients with diabetes compared to those
without diabetes [6, 17]. While we detected no differ-
ence in time to sputum culture conversion in the pre-
intervention period between matched patients with and
without diabetes, we found a decrease in time to
sputum culture conversion among patients with dia-
betes compared to those without diabetes in the post-
intervention period.
The validity of these observations was strengthened
by the complementary matched analyses. Importantly,
when patients with known diabetes were matched from
the pre and post-intervention periods, time to sputum
culture conversion decreased significantly by an average
of 20 days in the post-intervention group and the pro-
portion converting by 8 weeks increased to 80%. Given
the relationship of delayed culture conversion to re-
lapse of disease or the practice of extending treatment
duration for those that fail to culture convert by 8 weeks
and have cavitary lung disease [21, 23], these findings
may be clinically meaningful.
The improvement in microbiological outcomes for dia-
betes patients in the post-intervention period are suggest-
ive that the interventions early in the treatment course led
to this change. However, quantifying the effects of these
individual interventions remains challenging. Enhanced
case finding by more routine use of laboratory diagnostics
such as HbA1c testing, would have identified diabetes that
could have been undiagnosed in the pre-intervention
period. Additionally, this may explain the proportional in-
crease in diabetes patients among all TB cases between
the pre and post-intervention periods. Yet, during the
study periods, HbA1c testing was not required for report-
ing in the state registry, although now an initiative is in
place to make this testing available for all TB patients in
the state. Diagnosis alone would not improve treatment
outcomes unless patients with diabetes were treated
differently, and there is emerging evidence that metfor-
min may have anti-TB effects independent of control of
hyperglycemia by means of enhancing autophagy, a
form of mycobacterial killing by the host [24]. Unfortu-
nately, the surveillance data did not allow for detail of
the diabetic regimens.
It is also plausible that early TDM accounted for the
hastening in sputum culture conversion. A recent pro-
spective study from a TB endemic region demonstrated
that individual pharmacokinetic variability was the
primary driver of treatment failure [25]. Even in the
randomized controlled trial setting, higher doses of rifa-
pentine substituted for rifampin in the first-line therapy
for drug susceptible TB, time to culture conversion was
related to rifapentine exposure as measured by the area
under the time-concentration curve (AUC) from a full
pharmacokinetic sampling interval [26]. Future study of
rifapentine will use an AUC informed fixed dose not
because an individual’s drug exposure was unimportant
but because TDM is believed to be impractical for TB
endemic settings. Barriers to TDM implementation are
highlighted in a recent meta-analysis that aimed to
summarize the evidence for the use of TDM but found
generally low-quality observational studies from a few
specialized centers [27]. Still other individual studies
from well-resourced settings which have concluded that
TDM did not affect outcome have examined its use
only after patients have manifested slow response to
therapy where equivalence in outcome could instead be
interpreted as an actual benefit conferred by TDM in
preventing the more rare events of relapse or acquired
drug resistance [28]. In contrast in Virginia, recommen-
dations were made to use TDM systematically early in
the treatment course prior to the development of slow
response for a distinct subpopulation at higher risk of
poor treatment outcome.
Table 3 Sputum culture conversion in adults with pulmonary tuberculosis matched 2:1 non-diabetes to diabetes for age, gender,
sputum smear result and chest x-ray findings










Time to culture conversion (days, mean ± SD) 57 ± 35 61 ± 32 0.62 57 ± 37 42 ± 22 0.08
2 months culture conversion, No. (%) 34 (57) 15 (50) 0.55 31 (60) 21 (81) 0.12
Table 4 Sputum culture conversion in only diabetic patients
only matched 1:1 pre and post intervention for age, gender,






Time to culture conversion (days) 62 ± 31 42 ± 22 0.01
2 months’ culture conversion No. % 13 (50) 21 (80) 0.04
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Earlier studies of TDM are also limited in their hetero-
geneity of what drugs were assayed, what assays were
used for measurement and what concentrations were
used to prompt dose increase [29]. Even though isonia-
zid and rifampin both kill M. tuberculosis in a concen-
tration dependent manner, single or limited time points
as estimates of Cmax may imprecisely approximate the
AUC and the lower limits of the expected ranges for
these time points are extrapolated from smaller con-
trolled studies of TB patients or from healthy controls.
Certainly further study is needed to define pharmacokinetic
thresholds associated with outcome among a diversity of
patient populations with active TB [30] and relative to mini-
mum inhibitory concentrations. Our findings would suggest
that despite these inherent imprecisions, TDM when per-
formed with consistent procedures [11, 12] may provide a
clinically actionable result within a programmatic setting.
Older age diabetes patients comprise a growing pro-
portion of TB patients in Virginia, an epidemiological
trend we expect will be increasingly mirrored in other
locations as the global burden of diabetes expands and
dietary and/or lifestyle practices westernize among TB
prevalent communities. Without understatement, this
trend represents an emerging threat to TB control which
has prompted global stakeholders to call for a response
that capitalizes on the lessons learned from HIV related
TB [31]. For example, in Taiwan, the Bureau of National
Health Insurance has implemented a pay-for-performance
program for patients with diabetes and found a significant
decrease in the development of active TB compared to
diabetes patients not enrolled in the program and a de-
crease in death from TB during treatment relative to
diabetes patients not enrolled and non-diabetes patients
[32]. Strategies that have integrated HIV and TB diagnos-
tics and therapy have achieved remarkable success in
the era of antiretroviral rollout even for drug-resistant
TB [33, 34], and similarly bold approaches may be
necessary for diabetes related TB.
There are several other limitations in this study, given
the retrospective, non-randomized design and inability to
capture definitive laboratory data on all patients including
those that were categorized as not having diabetes when
laboratory diagnostics for diabetes may simply not have
been performed. However, this potential misclassification
would not have affected the matched comparison of pa-
tients with known diabetes pre and post-intervention.
While the improvement in time to culture conversion was
maintained when the analysis was restricted to those with
known early TDM performed, clinicians may not have
followed the recommendations for dose adjustment and
the influence of the final dose or regimen could not be es-
timated. It is also possible that those patients with diabetes
Fig. 2 C2hr results for early therapeutic drug monitoring among diabetes patients in the post-intervention group. Boxes= interquartile ranges with
median line, whiskers= minimum and maximum values, and one circle (for isoniazid) is a statistical outlier. Brackets represent the expected range
for the Cmax; isoniazid 3-5 μg/ml and rifampin 8-24 μg/ml
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that had early interventions were monitored more inten-
sively with more frequent sputum samples but this would
be unlikely in a programmatic setting and the magnitude
of improvement in the diabetes patients from pre to post-
intervention would not be expected from more frequent
sampling alone. As markers of diabetes disease severity
were not routinely measured in the registry, it remains
possible that post-intervention patients with diabetes had
less severe stages of diabetes disease that could have
accounted for some of the improved clinical response.
Other confounders were not immediately apparent.
Conclusions
In summary, early interventions for diabetes related TB
in the programmatic setting hasten sputum culture
conversion but require validation in other diabetes
prevalent populations, including further prospective
study on the relative impact of early TDM and its effect
on other longer term clinical outcomes such as treat-
ment duration, relapse or with regard to TB endemic
settings, early treatment failure. At a minimum, these
findings highlight the need for dedicated attention to
this emerging co-epidemic.
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